Milestone Pharmaceuticals Inc
MIST
Company Profile
Business description
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
Contact
1111 Dr. Frederik-Phillips Boulevard
Suite 420
MontrealQCH4M 2X6
CANT: +1 514 336-0444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
38
Stocks News & Analysis
stocks
Our view after Coles’ shares plunge
Shares dropped 8% after reporting results for the September 2026 quarter.
stocks
Cheap ASX share remains overlooked by the market
Fear outweighs fundamentals as ASX share reaffirms outlook.
stocks
Microsoft earnings: Azure accelerates, but investment returns remain the test
We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,977.20 | 48.20 | -0.53% |
| CAC 40 | 7,969.42 | 0.58 | -0.01% |
| DAX 40 | 25,818.21 | 221.47 | -0.85% |
| Dow JONES (US) | 51,770.31 | 572.25 | -1.09% |
| FTSE 100 | 10,729.78 | 7.71 | 0.07% |
| HKSE | 23,455.98 | 161.56 | 0.69% |
| NASDAQ | 25,437.00 | 747.73 | -2.86% |
| Nikkei 225 | 63,284.94 | 5.17 | -0.01% |
| NZX 50 Index | 13,698.63 | 98.37 | -0.71% |
| S&P 500 | 7,580.07 | 140.32 | -1.82% |
| S&P/ASX 200 | 8,856.50 | 51.60 | -0.58% |
| SSE Composite Index | 3,633.36 | 34.34 | 0.95% |